Advances in endocrine and targeted therapy for hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
Abstract. Nearly 70% of breast cancer (BC) is hormone-receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, and endocrine therapy is the mainstay of treatment for this subtype. However, intrinsic or acquired endocrine resistance can occur during the endocrine treatment. B...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer
2020-05-01
|
Series: | Chinese Medical Journal |
Online Access: | http://journals.lww.com/10.1097/CM9.0000000000000745 |
id |
doaj-a33b1c3160744c508492fb263dd85b85 |
---|---|
record_format |
Article |
spelling |
doaj-a33b1c3160744c508492fb263dd85b852020-12-02T07:57:48ZengWolters KluwerChinese Medical Journal0366-69992542-56412020-05-0113391099110810.1097/CM9.0000000000000745202005050-00015Advances in endocrine and targeted therapy for hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancerLe-Sang ShenXiao-Yan JinXu-Meng WangLai-Zhen TouJian HuangQiang ShiAbstract. Nearly 70% of breast cancer (BC) is hormone-receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, and endocrine therapy is the mainstay of treatment for this subtype. However, intrinsic or acquired endocrine resistance can occur during the endocrine treatment. Based on insights of endocrine resistance mechanisms, a number of targeted therapies have been and continue to be developed. With regard to HR-positive, HER2-negative advanced BC, aromatase inhibitor (AI) is superior to tamoxifen, and fulvestrant is a better option for patients previously exposed to endocrine therapy. Targeted drugs, such as cyclin-dependent kinases (CDK) 4/6 inhibitors, mammalian target of rapamycin (mTOR) inhibitors, phosphoinositide-3-kinase (PI3K) inhibitors, and histone deacetylase (HDAC) inhibitors, play a significant role in the present and show a promising future. With the application of CDK4/6 inhibitors becoming common, mechanisms of acquired resistance to them should also be taken into consideration.http://journals.lww.com/10.1097/CM9.0000000000000745 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Le-Sang Shen Xiao-Yan Jin Xu-Meng Wang Lai-Zhen Tou Jian Huang Qiang Shi |
spellingShingle |
Le-Sang Shen Xiao-Yan Jin Xu-Meng Wang Lai-Zhen Tou Jian Huang Qiang Shi Advances in endocrine and targeted therapy for hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer Chinese Medical Journal |
author_facet |
Le-Sang Shen Xiao-Yan Jin Xu-Meng Wang Lai-Zhen Tou Jian Huang Qiang Shi |
author_sort |
Le-Sang Shen |
title |
Advances in endocrine and targeted therapy for hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer |
title_short |
Advances in endocrine and targeted therapy for hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer |
title_full |
Advances in endocrine and targeted therapy for hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer |
title_fullStr |
Advances in endocrine and targeted therapy for hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer |
title_full_unstemmed |
Advances in endocrine and targeted therapy for hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer |
title_sort |
advances in endocrine and targeted therapy for hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer |
publisher |
Wolters Kluwer |
series |
Chinese Medical Journal |
issn |
0366-6999 2542-5641 |
publishDate |
2020-05-01 |
description |
Abstract. Nearly 70% of breast cancer (BC) is hormone-receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, and endocrine therapy is the mainstay of treatment for this subtype. However, intrinsic or acquired endocrine resistance can occur during the endocrine treatment. Based on insights of endocrine resistance mechanisms, a number of targeted therapies have been and continue to be developed. With regard to HR-positive, HER2-negative advanced BC, aromatase inhibitor (AI) is superior to tamoxifen, and fulvestrant is a better option for patients previously exposed to endocrine therapy. Targeted drugs, such as cyclin-dependent kinases (CDK) 4/6 inhibitors, mammalian target of rapamycin (mTOR) inhibitors, phosphoinositide-3-kinase (PI3K) inhibitors, and histone deacetylase (HDAC) inhibitors, play a significant role in the present and show a promising future. With the application of CDK4/6 inhibitors becoming common, mechanisms of acquired resistance to them should also be taken into consideration. |
url |
http://journals.lww.com/10.1097/CM9.0000000000000745 |
work_keys_str_mv |
AT lesangshen advancesinendocrineandtargetedtherapyforhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativeadvancedbreastcancer AT xiaoyanjin advancesinendocrineandtargetedtherapyforhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativeadvancedbreastcancer AT xumengwang advancesinendocrineandtargetedtherapyforhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativeadvancedbreastcancer AT laizhentou advancesinendocrineandtargetedtherapyforhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativeadvancedbreastcancer AT jianhuang advancesinendocrineandtargetedtherapyforhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativeadvancedbreastcancer AT qiangshi advancesinendocrineandtargetedtherapyforhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativeadvancedbreastcancer |
_version_ |
1724407918705508352 |